Modified DCF (mDCF, docetaxel cisplatin 5FU) for patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) unfit to DCF: A retrospective study.

Clara Delaruelle,A. Ambrun,Clémentine Daveau,Marc Poupart,Philippe Zrounba,Eve-Marie Neidhardt,Philippe Ceruse,Antoine Ramade,Jérôme Fayette

Modified DCF (mDCF, docetaxel cisplatin 5FU) for patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) unfit to DCF: A retrospective study.

2014

Clara Delaruelle
A. Ambrun
Clémentine Daveau
Marc Poupart
Philippe Zrounba
Eve-Marie Neidhardt
Philippe Ceruse
Antoine Ramade
Jérôme Fayette

e17018 Background: DCF is the standard chemotherapy for induction in LASCCHN. Its toxicity reserves it to younger patients (pts) without comorbidity and of PS 0-1. In gastric cancer mDCF demonstrat...

Keywords:

Carcinoma
Cisplatin
Pathology
Retrospective cohort study
Cancer research
Medicine
Docetaxel
Cancer
Oncology
Comorbidity
Internal medicine
Toxicity
Chemotherapy
head and neck

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations